Showing 6461-6470 of 8236 results for "".
- Analysis Reveals How Incurable Skin Cancer Resists Treatmenthttps://practicaldermatology.com/news/research-autopsies-reveals-how-incurable-skin-cancer-resists-treatment/2461637/A new analysis published in the journal Cancer Discovery reveals how some skin cancers stop responding to treatment at the end of l
- Bristol Myers Squibb Receives European Commission Approval of Sotyktu for Plaque Psoriasishttps://practicaldermatology.com/news/bristol-myers-squibb-receives-european-commission-approval-of-sotyktu-for-plaque-psoriasis/2461634/The European Commission has approved Sotyktu (deucravacitinib; Bristol Myers Squibb), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy. The approval was
- New North Carolina Courage Jerseys to Feature Merz Aesthetics Sponsorshiphttps://practicaldermatology.com/news/new-north-carolina-courage-jerseys-to-feature-merz-aesthetics-sponsorship-1/2461632/Merz Aesthetics North America has launched its front-of-jersey sponsorship deal with the
- New Way to Measure Skin Barrier Function Identifiedhttps://practicaldermatology.com/news/new-way-to-measure-skin-barrier-function-identified/2461628/Scientists in Japan have devised a new way to measure skin barrier function. Most methods indirectly calculate skin barrier function using a proxy measure called transepidermal water loss (TEWL), but the dependance on a heavily controlled environment is one of the primary limitations of this
- HS Update: Studies Suggest TNF, IL-17, and JAK inhibitors May Play a Role in Treating HShttps://practicaldermatology.com/news/hs-update-studies-suggest-tnf-il-17-and-jak-inhibitors-may-play-a-role-in-treating-hs/2461627/Several new potential therapies for hidradenitis suppurativa (HS) are coming down the pike, according to research presented at the 2023 American Academy of Dermatology (AAD) Annual Meeting in New Orleans. Acelyrin, Inc.'s Izokibep led to HiSCR response at 12 weeks, including H
- OliX Pharmaceuticals to Start Phase 1 Trial of Androgenic Alopecia Treatmenthttps://practicaldermatology.com/news/olix-pharmaceuticals-to-start-phase-1-trial-of-androgenic-alopecia-treatment/2461626/OliX Pharmaceuticals received regulatory approval to start Phase 1 trial of androgenic alopecia treatment in Australia. The trial is a multi-center, randomized, double-blind, placebo-controlled, and single ascending dose Phase 1 study. The primary objective of the study is to evalu
- Aquavit Files Additional IND for New Toxin for Palmar Hyperhidrosishttps://practicaldermatology.com/news/aquavit-files-additional-ind-for-new-toxin-for-palmar-hyperhidrosis/2461625/Aquavit Holdings is asking the US Food and Drug Administration for an additional IND for DTX-024, a treatment of palmar hyperhidrosis using the company’s patented microchannel technology. DTX-024 is a highly purified and clinically tested injectable neuromodulator derived fr
- Takeda’s TYK2 Blocker Impresses in Phase 2b PsO Studyhttps://practicaldermatology.com/news/takedas-tyk2-blocker-impresses-in-phase-2b-pso-study/2461622/Takeda’s TYK2 inhibitor TAK-279 performed well in a Phase 2b study of patients with moderate-to-severe plaque psoriasis. TAK-279 was developed by Nimbus Therapeutics and owned by Takeda. The new findings were presented at the 2023 American Academy of Dermatology (AAD) An
- Timber Pharmaceuticals Announces Publication of Sub-Analysis of Phase 2b CONTROL Studyhttps://practicaldermatology.com/news/timber-pharmaceuticals-announces-publication-of-sub-analysis-of-phase-2b-control-study/2461620/Timber Pharmaceuticals announced the online publication of a sub-analysis of the Phase 2b CONTROL study, which is evaluating TMB-001, a topical isotretinoin formulated using the company’s patented IPEG delivery system, in subjects 9 years of age and older with moderate t
- Galderma's IL-31 Blocker Nemolizumab Wows in PNhttps://practicaldermatology.com/news/galdermas-il-31-blocker-nemolizumab-wows-in-pn/2461619/Galderma’s nemolizumab performed well in Prurigo Nodularis (PN). Nemolizumab is a first-in-class investigational monoclonal antibody directed against the IL-31 receptor alpha that blocks signaling from IL-31.Nemolizumab is an investigational drug and Galderma has not received